There is growing evidence, however, that β-catenin activation may occur through cues other than those involved in Wnt signaling, for example, the epidermal growth factor receptor (EGFR) in melanoma [20] and the androgen receptor (AR) in prostate cancer, which was found to be a target of Wnt [104]. This evidence concerns the gene AR and prostate carcinoma.